Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endo International PLC to acquire DAVA Pharmaceuticals, Inc


Tuesday, 24 Jun 2014 09:10am EDT 

Endo International PLC:Reaches definitive agreement to acquire DAVA Pharmaceuticals, Inc for $575 mln in cash, with additional cash consideration of up to $25 mln contingent on achievement of certain sales milestones.Oppenheimer & Co. Inc. is acting as lead financial advisor to DAVA Pharmaceuticals and Dechert LLP is acting as DAVA's legal counsel.Jefferies LLC also advised DAVA on the transaction. 

Company Quote

63.28
-0.53 -0.83%
21 Aug 2014